Orthocell (ASX:OCC) requested a trading halt with the Australian bourse on Monday ahead of an announcement on the new regulatory approval for its peripheral nerve reconstruction device Remplir, according to a same-day filing with the Australian bourse.
The trading halt will remain until Wednesday or when the announcement is released, the filing said.
Before the halt, the regenerative medicine firm's shares rose to their highest since October 2022.
Price (AUD): $0.48, Change: $+0.020, Percent Change: +4.35%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.